EBAC
 
 
Powered by
EBAC on-line Accreditation Services Home | Discover EBAC on-line services | FAQ | Contact us
EBAC calendars
Events CDROMs
Web courses Articles to select a Calendar use this horizontal tabs
Search EBAC Web calendar
Keywords:
Additional search criteria:
Display archived modules (accreditation expires after 2 years)

Web calendar

Current selection criteria: No criteria
Click on a column name to sort the list
CME Provider Website title Module CME credits Expiry
Academic Medical Center Amsterdam. Dept Vascular Medicine
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc HbA1c in CVD 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc Hypoglycemia in CV medicine - why worry? 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc Key classes of antidiabetic drugs 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc Natural history of diabetes: focus on microvascular and macrovascular complications 1 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein 5 Things a cardiologist needs to know about diabetes - https://pace-cmelearninglab.coursepath.com/1509890/course-toc T2DM and CV outcomes 0 04 Jun 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc Early intervention for lifetime CV risk reduction 1 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc Estimating CV risk and treatment benefit 0 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc Importance of hypertension in CVD prevention 0 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Clinical updates in management of cardiovascular risk - https://academy1745879297.coursepath.com/1706498/course-toc The role of lipids in CVD prevention: Lessons learned about statins 0 07 Aug 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses Insights from the first trials in epigenetics in human: What is the way forward? 1 24 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do? 1 24 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Managing Diabetes & CVD: Is epigenetics a new way forward? - https://academy1745879297.coursepath.com/my-courses Promise of epigenetic modulation as a target in atherosclerotic patients. 1 24 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses Heart failure & Diabetes: Time for a more unified approach 1 09 Dec 2019
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses Management of CV Risk & T2DM: Implications of novel outcome trials 1 09 Dec 2019
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure - https://academy1745879297.coursepath.com/my-courses SGLT2 inhibition in cardiology: What a cardiologist needs to know 1 09 Dec 2019
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials 1 25 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses PCSK9 inhibition across a wide spectrum of patients: For whom is it efficacious? 1 25 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies - https://academy1745879297.coursepath.com/my-courses Understanding new PCSK9 outcome data: From the LDL 1 25 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc Diagnosis, classification of patients, prognosis 0 23 May 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc Future perspectives 0 23 May 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc Treatment options, follow-up of non-responsive patients, optimization of therapy 0 23 May 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Pulmonary arterial hypertension - key questions addressed - https://pace-cmelearninglab.coursepath.com/1640962/course-toc Underlying pathophysiology, characteristics, clinical subgroups, prevalence and risk factors 1 23 May 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses Challenging CV risk in diabetes: Ready for a new approach? 0 24 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses Heart failure & diabetes: SGLT2 inhibition, a paradigm shift? 0 24 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? - https://academy1745879297.coursepath.com/my-courses SGLT-2 inhibitors in T2DM Management: Current position & future promise 0 24 Jan 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc Inflammation & CVD: Translating insights from vascular biology to the clinic 0 07 May 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc The CANTOS trial: Implications for the management of patients with residual risk 0 07 May 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc The new era of residual risk reduction 0 07 May 2020
Academic Medical Center Amsterdam. Dept Vascular Medicine/ J. Kastelein Targeting residual risk with anti-inflammatory therapies - https://pace-cmelearninglab.coursepath.com/1575426/course-toc The patient with inflammatory residual risk: Who is it? 1 07 May 2020
Faculte de Medecine Pierre et Marie Curie
Faculte de Medecine Pierre et Marie Curie/ A. Carrie e-learning on genetic testing in FH - http://elearning.cor2ed.com/ Genetic testing and diagnosis of FH 1 10 Jan 2019
Maastricht University Medical Center
Maastricht University Medical Center/ H. Crijns Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage Case study: Successful AF ablation program - perils, pitfalls and tricks 0 17 May 2020
Maastricht University Medical Center/ H. Crijns Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage Introduction: What is the value of a multidisciplianry AF Heart Team? 1 17 May 2020
Maastricht University Medical Center/ H. Crijns Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage What are the practical considerations for implementing a MDT Heart Team in your hospital? 0 17 May 2020
Maastricht University Medical Center/ H. Crijns Radcliffe CME - https://www.radcliffe-cme.com/user/login?destination=homepage What evidence exists to support hybrid ablation? 0 17 May 2020
The University of Edinburgh
The University of Edinburgh/ K. Fox Achieving Long-Term Protection Post-MI: The Accumulated Evidence - http://www.medscape.org/ Achieving Long-Term Protection Post-MI: The Accumulated Evidence 1 22 Aug 2018
The University of Edinburgh/ K. Fox Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum - http://www.medscape.org/ Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum 1 27 Oct 2018
The University of Edinburgh/ K. Fox CV Risk Doesn't End in the Cath Lab: Event-Free Survival Is a Lasting Commitment - http://www.medscape.org CV Risk Doesn't End in the Cath Lab: Event-Free Survival Is a Lasting Commitment 1 09 Dec 2019
The University of Edinburgh/ K. Fox Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials - http://www.staging.medscape.org/viewarticle/876882 Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials 1 28 May 2019
The University of Edinburgh/ K. Fox Improving ACS Outcomes: Acute Treatment and Chronic Management - http://www.staging.medscape.org/viewarticle/882603 Improving ACS Outcomes: Acute Treatment and Chronic Management 1 22 Aug 2019
The University of Edinburgh/ K. Fox Optimal Antiplatelet Therapy in the Patient With PAD: Are We There? - http://www.medscape.org/ Optimal Antiplatelet Therapy in the Patient With PAD: Are We There? 1 27 Oct 2018
The University of Edinburgh/ K. Fox PAD Patients vs Post-ACS Patients: Insights From Antiplatelet Trials - http://www.staging.medscape.org/viewarticle/873056 PAD Patients vs Post-ACS Patients: Insights From Antiplatelet Trials 1 18 Jan 2019
UpToDate
UpToDate/ T. Post https://uptodate.com - https://www.uptodate.com UpToDate 1 14 Mar 2020

Privacy policy | Terms & conditions | Document library | Contact us     Copyright © 2008-2018 EBAC - All rights reserved